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Introduction 14
Adjuvant systemic therapy has improved survival among breast cancer patients, the 15 majority of which have estrogen receptor (ER)-positive, human epidermal growth 16 factor receptor type 2 (HER2)-normal disease. For patients with this subtype, 17 adjuvant endocrine therapy is usually recommended, often in combination with 18 chemotherapy. One of the greatest challenges within this group of patients is to 19 identify those with good prognosis for whom chemotherapy can be avoided [1] . In Histological grade (G) has repeatedly been shown to be a strong and independent 6 prognostic factor [3] [4] [5] , however, in 2013 the majority of St Gallen expert panelists 7 voted that G3 could not be used as a substitute for high . In contrast, in a 8 pilot study that investigated the role of G in breast cancer prognosis in addition to 9 that afforded by the 2013 St Gallen classification system we found that in 161 10 premenopausal lymph node-negative patients with ER-positive/HER2-normal breast 11 cancer, G was strongly associated with St Gallen subtypes [7] . Indeed, ´Luminal A-12 like´ were mostly G1 or G2, whereas ´Luminal B-like´ were usually G2 or G3 [6] . Of 13 the cases that diverged, a follow-up period of 10 years revealed that two out of four 14 patients with ´Luminal A-like´ G3 breast cancer developed distant metastases and 15 hence had a prognosis more similar to that of ´Luminal B-like´ breast cancer, 16 whereas of the three patients with ´Luminal B-like´ breast cancer that were G1, not 17 one experienced relapse and thus their clinical outcome was more similar to that of 18 ´Luminal A-like´ breast cancer. These results, although based on a small number of 19 cases, suggest that, independent of PgR and Ki-67, patients with ER-positive/HER2-20 normal breast cancers that are G1 might have a better prognosis than those with G3.
21
The primary aim of the present investigation was to use independent patient series to 22 confirm the additional prognostic value of G to that of the 2013 St Gallen surrogate 23 classification of ER-positive/HER2-normal breast cancer. We hypothesized that for 1 the ER-positive/HER2-normal subgroup of patients, G would be the first 2 discriminator for those with G1 or G3 tumors, while Ki-67 and PgR would provide 3 additional prognostic information specifically for patients with G2 tumors. As a 4 secondary aim, the prognostic importance of PgR and Ki-67 was evaluated in 5 patients with G2, ER-positive/HER2-normal breast cancer. For the primary aim, we included breast cancer patients from two randomized 10 multicenter trials (Patient series I and II) and one additional cohort (Patient series III) 11 (Table 1) . Patients with complete information regarding follow-up, number of 12 positive lymph nodes, tumor size, ER, PgR, HER2, Ki-67, and G were included 13 (Figure 1). Patients with at least one of the following characteristics were excluded: 14 ER negativity, HER2 positivity, <35 years of age, >4 positive lymph nodes, tumor 15 size >50 mm. Patients with these characteristics are most likely candidates for 16 adjuvant chemotherapy without consideration of other prognostic factors.
17
For the second aim, an additional 110 patients with G2 tumors were included (Patient 18 series IV; see below). These patients were not included when addressing the primary 19 aim as they were part of the pilot study [6] . The expression levels of ER, PgR, Ki-67, and HER2 were evaluated on whole 8 sections or tissue microarrays as previously described [7, 12, 13] . Two core biopsies 9 were evaluated from each formalin-fixed, paraffin-embedded breast cancer tissue, 10 and the one with the highest percentage of positively stained cells was chosen. All 11 cores were 0.6 mm in diameter with the exception of those used for ER and PgR 12 analyses in Patient material IV that were 1.0 mm in diameter. To further assess prognostic factors in our study cohort, multivariable analysis was 2 performed including G, St Gallen subtypes, tumor size, lymph node status, and 3 patient age. Among these, only G and lymph node status were found to be significant 4 prognostic factors (Table 3a) . Similar results were obtained when patients treated 5 with adjuvant endocrine therapy were analyzed separately (Table 3b ). In the present study, histological grade (G) added prognostic information to that profiling, it has previously been shown that patients with histological grade 2 tumors 8 in a similar way could be subdivided into one group with good prognosis and one 9 group with poor prognosis [14] . It is interesting to note that most of these genes were 10 associated to cell cycle regulation and proliferation. The patients in our study were 11 selected from two randomized trials and two prospectively collected cohorts, and 12 were diagnosed between 1983 and 2003. In three of these series, the selection of for other cut-offs in this interval, but we have not explored that in the present dataset.
4
Instead we stick to the pre-defined cut-off 20%. One drawback with G, however, is its limited inter-observer reproducibility [22, 23] .
8
In spite of this, it has repeatedly been shown to be a strong prognostic factor [3] [4] [5] . 9 Furthermore, it is cheap and easily evaluated routinely in the clinical setting. Also, 10 by using strict guidelines, the concordance between different evaluators can be 11 improved [24] . In this context, it should be mentioned that limited inter-observer 12 reproducibility is also a well-known problem for . 
